安旭生物(688075) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥155,111,696.94, representing a year-on-year increase of 38.78%[2] - The net profit attributable to shareholders for the same period was ¥20,464,686.12, showing a slight increase of 1.99% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥493,907.84, a significant increase of 4,408.83% year-on-year[2] - The company experienced a decrease in net profit attributable to shareholders of 27.33% year-on-year, primarily due to a decline in the USD exchange rate compared to the same period last year[6] - Total operating revenue for the first three quarters of 2024 reached CNY 403,268,418.25, a significant increase from CNY 316,140,350.49 in the same period of 2023, representing a growth of approximately 27.5%[12] - Operating profit for the first three quarters of 2024 was CNY 144,005,689.94, down from CNY 211,124,693.33 in 2023, reflecting a decrease of approximately 31.7%[13] - Net profit for the first three quarters of 2024 was CNY 135,748,290.64, compared to CNY 186,362,914.02 in the same period of 2023, showing a decline of about 27.1%[13] - The net profit attributable to the parent company for Q3 2024 is ¥135,783,697.44, a decrease of 27.3% from ¥186,839,773.09 in Q3 2023[14] - The total comprehensive income for Q3 2024 is ¥143,387,343.88, down from ¥187,068,818.14 in Q3 2023, reflecting a decline of 23.4%[14] - The basic and diluted earnings per share for Q3 2024 are both ¥1.07, compared to ¥1.47 in Q3 2023, indicating a decrease of 27.2%[14] Research and Development - Research and development expenses totaled ¥27,424,786.32, accounting for 17.68% of operating revenue, a decrease of 2.39% from the previous year[3] - R&D investment for the reporting period reached RMB 39.42 million, reflecting an increase in R&D expenses[7] - Research and development expenses for the first three quarters of 2024 amounted to CNY 77,098,514.21, an increase from CNY 68,008,768.32 in 2023, representing a growth of approximately 13.5%[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,797,002,474.77, a slight increase of 0.13% from the end of the previous year[3] - The total assets of the company as of the end of the third quarter of 2024 were CNY 5,797,002,474.77, slightly up from CNY 5,789,539,225.57 at the end of 2023[11] - Total liabilities as of the end of the third quarter of 2024 were CNY 649,569,436.05, down from CNY 683,827,286.72 in 2023, indicating a decrease of about 5.0%[11] - The company's total non-current assets were CNY 958,058,703.67, a slight decrease from CNY 977,816,584.07 in the previous year[11] Cash Flow - The company reported a net cash flow from operating activities of ¥24,260,942.83 for the year-to-date period[2] - Cash flow from operating activities for the first three quarters of 2024 is ¥24,260,942.83, a significant improvement from a net cash outflow of ¥684,387,106.20 in the same period of 2023[15] - Cash inflow from investment activities for the first three quarters of 2024 is ¥5,432,949,561.05, down from ¥8,153,744,355.18 in the same period of 2023[15] - Cash outflow from investment activities for Q3 2024 is ¥5,532,055,771.49, compared to ¥8,468,341,778.71 in Q3 2023, showing a decrease of 34.5%[16] - The net cash flow from investment activities for Q3 2024 is -¥99,106,210.44, an improvement from -¥314,597,423.53 in Q3 2023[16] - The cash and cash equivalents at the end of Q3 2024 amount to ¥181,017,444.31, down from ¥724,290,399.91 at the end of Q3 2023[16] - The company reported a decrease in cash received from sales of goods and services, totaling ¥361,389,976.80 for the first three quarters of 2024, compared to ¥469,267,460.47 in the same period of 2023, a decline of 22.9%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,697, with the largest shareholder holding 26.87%[8] - The top ten shareholders collectively hold 59.79% of the company's shares, indicating a concentrated ownership structure[8] - The company has not reported any significant changes in shareholder relationships or actions regarding margin trading[8] Operational Insights - The company continues to implement an innovation-driven strategy, enhancing its market share in the in-vitro diagnostics sector[6] - There are no significant reminders or additional important information regarding the company's operational performance during the reporting period[9] - The company has not reported any new product launches or significant market expansion strategies during this quarter[17]